Targeted, purpose-built medicines for serious chronic disease
We aim to change the course of serious chronic disease with precision-engineered medicines designed around patient need, disease biology, and the real-world settings where care happens.
Our lead program, Rev-56, is focused on non-CF bronchiectasis (NCFB), a severe and progressive respiratory disease affecting an estimated 350,000 to 500,000 adults in the United States, and millions more worldwide; many live with a chronic infection that drives worse outcomes and higher healthcare costs.
Rev-56 is a first-in-class inhaled precision-engineered therapy that is entering Phase 1 clinical development in 2026—purpose-built for NCFB and the demands of inhaled delivery at the site of disease.
Rev-56 anchors a focused pipeline, with selective expansion into other chronic and recurrent conditions over time — rooted in the same disciplined, biology-driven design as our lead program.
The Revagenix team brings deep, hands-on experience advancing fit-for-market medicines across the full life cycle, from discovery through commercialization.
